Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
GlucoTrack Inc
GCTK
Healthcare
Biotechnology
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a...
sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GCTK)
New Post
View:
Posts & Comments
Threaded Posts
(1)
•••
Palindrome808
X
Post by
Palindrome808
on May 06, 2025 1:25pm
Just Voted...
GCTK is asking for the board to remain as is in addition to approve a RS to $0.0001. Sounds interesting.
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 30, 2025 6:21am
GCTK....volume on no News..pre RS to be voted on
I call this a Pre RS Pump ; ) There might be a trade in it but...u just could be the one holdingan expensive bag No position
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 16, 2025 9:43am
GCTK.....Buh Bye
Bored stiff
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 10, 2025 2:38pm
GCTK.....Been a shareholder for about 1 week
Never say never Buy Hold & Prosper...17 cents
(1)
•••
Palindrome808
X
Comment by
Palindrome808
on Mar 31, 2025 4:33pm
RE:Volume of 2k
I agree that Big Pharma will target this firm when successful and take it to another level... The key question is which Big Pharma? (Captin Obvious moment: The answer is whose offer is the most
...more
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 01, 2024 7:21pm
GlucoTrack, Inc. (NASDAQ:GCTK) – A Promising Implantab
https://beyondspx.com/2024/08/01/glucotrack-inc-nasdaqgctk-a-promising-implantable-glucose-monitoring-solution-amidst-challenges/
(294)
•••
TrevorAbes
X
Post by
TrevorAbes
on Nov 17, 2023 5:24pm
Three of the best penny stocks with competitive advantages
https://stockhouse.com/news/newswire/2023/11/17/three-best-penny-stocks-with-competitive-advantages
(441)
•••
Dibah420
X
Post by
Dibah420
on Jan 19, 2023 1:50pm
Volume of 2k
.. for what is essentially a penny stock implies they need some pith in their product line in order to promote. The concept nonethless has promise and the market HUGE. If it works then
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Healthcare and Clinical Stage Drug Development Company Acquires NoBrainer Imaging Centers